Home › Funds › Van Berkom & Associates Inc. › CRL
Van Berkom & Associates Inc. position in CRL
CHARLES RIV LABS INTL INC · Health Care
Van Berkom & Associates Inc. reported holding 285,107 shares of CRL (CHARLES RIV LABS INTL INC) in its Q3 2026 13F filing — a position valued at US$84.1M, representing 3.00% of its reported portfolio and ranking #7 among its reported holdings. Van Berkom & Associates Inc. has disclosed CRL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Van Berkom & Associates Inc.'s CRL position evolved
Van Berkom & Associates Inc. first disclosed a stake in CRL in Q3 2023 at 222,198 shares (US$43.5M). The position peaked in Q2 2026 at 449,414 shares, worth US$101.9M. Across 13 filings, Van Berkom & Associates Inc. increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 285,107 shares valued at US$84.1M — a reduction of -164,307 shares quarter over quarter.. Notable position changes include a 43% increase in Q4 2023 (shares rose 15% over the following quarter), a 37% trim in Q3 2026 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 222.20K | $43.55M | New |
| Q4 2023 | 318.41K | $75.27M | Add |
| Q1 2024 | 311.47K | $84.39M | Reduce |
| Q2 2024 | 318.23K | $65.74M | Add |
| Q3 2024 | 389.83K | $76.79M | Add |
| Q4 2024 | 388.00K | $71.62M | Hold |
| Q1 2025 | 447.09K | $67.30M | Add |
| Q2 2025 | 486.95K | $73.89M | Add |
| Q3 2025 | 496.91K | $77.75M | Add |
| Q4 2025 | 450.69K | $89.90M | Reduce |
| Q1 2026 | 501.15K | $86.45M | Add |
| Q2 2026 | 449.41K | $101.92M | Reduce |
| Q3 2026 | 285.11K | $84.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRL and 13F data
CRL (CHARLES RIV LABS INTL INC) is a Health Care company. 29 other funds we track also report a position in CRL — the largest reported positions include ARIEL INVESTMENTS, LLC (US$352.0M), EARNEST PARTNERS LLC (US$320.7M), Allspring Global Investments Holdings, LLC (US$254.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRL
- ARIEL INVESTMENTS, LLC 1.19M sh · $352.05M · Q3 2026
- EARNEST PARTNERS LLC 1.09M sh · $320.67M · Q3 2026
- Allspring Global Investments Holdings, LLC 887.52K sh · $254.57M · Q3 2026
- COOKE & BIELER LP 432.12K sh · $127.48M · Q3 2026
More on Van Berkom & Associates Inc.
FAQ
How long has Van Berkom & Associates Inc. held CRL?
Van Berkom & Associates Inc. has disclosed CRL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Van Berkom & Associates Inc.'s current position in CRL?
As of Q3 2026, Van Berkom & Associates Inc. holds 285.11K shares of CRL (CHARLES RIV LABS INTL INC), valued at $84.11M, representing 3.00% of its reported portfolio and ranking #7.
Has Van Berkom & Associates Inc. been buying or selling CRL?
In the latest 13F filing (Q3 2026), Van Berkom & Associates Inc. reduced its position in CRL. The position peaked in Q2 2026 at 449.41K shares.
Which other funds hold CRL?
Other major institutional holders of CRL include ARIEL INVESTMENTS, LLC, EARNEST PARTNERS LLC, Allspring Global Investments Holdings, LLC, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.